Status:
UNKNOWN
Study of Biomarkers That Predict the Evolution of Huntington's Disease
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Huntington Disease
Eligibility:
All Genders
18+ years
Brief Summary
Huntington's disease (HD) is a rare, autosomal dominant, progressive neurodegenerative disorder typically becoming noticeable in middle age. It is clinically characterized by progressive involuntary m...
Detailed Description
In this context, we propose to focus our research not only on biological and genetic markers but also on neuroimaging and neuropsychological markers using paradigms of time reactions or measurement of...
Eligibility Criteria
Inclusion
- Inclusion Criteria (patient):
- Voluntary patients symptomatic or asymptomatic
- Patient with a number of CAG ≥36)
- Patient who know his genetic status
- Age greater than 18 years or equal to 18 years
- Patient who provided written informed consent
- Exclusion Criteria (patient):
- \- Deterioration of the protocol preventing the understanding of the protocol
- Inclusion Criteria (control):
- Voluntary controls with no family history of huntington's disease
- Control with a number of CAG \<36
- Age greater than 18 years or equal to 18 years
- Control who provided written informed consent
- Exclusion Criteria (control):
- \- Deterioration of the protocol preventing the understanding of the protocol
Exclusion
Key Trial Info
Start Date :
September 1 2003
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2021
Estimated Enrollment :
1800 Patients enrolled
Trial Details
Trial ID
NCT01412125
Start Date
September 1 2003
End Date
January 1 2021
Last Update
October 9 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Henri Mondor
Créteil, France, 94010